Linerixibat decreased serum interleukin-31 levels in patients with primary biliary in cholangitis after 24 weeks, which may ...

Seladelpar (Livdelzi) provided sustained pruritus relief for up to 30 months in patients with primary biliary cholangitis ...

A pooled analysis of two phase 3 clinical trials shows that the first-in-class drug improves itching and itching-related ...

NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, ...

New data from the ELATIVE ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Itch is a devastating symptom sometimes in ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met its primary endpoint. The U.K. drugmaker ...

GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational targeted inhibitor of the ileal bile acid transporter (IBAT), linerixibat, for ...

(RTTNews) - GSK plc (GSK), Monday confirmed that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational ileal bile acid transporter ...

Seeking to rejuvenate itself after recent disappointments, Gilead Sciences Inc. proposes to bolster its liver portfolio by taking over Cymabay Therapeutics Inc. for $32.50 per share in cash, a total ...

Gilead’s Livdelzi demonstrates sustained efficacy in PBC, offering ALP reduction, itch relief and potential to slow disease progression: Foster City, California Monday, November ...